Lifestyle
- Quit smoking
- Reduce alcohol consumption
- Manage diabetes
- Exercise regularly
Homocysteine · Hcy · tHcy
Homocysteine measures the concentration of this amino acid in the blood, reflecting methionine metabolism and methylation cycle efficiency.
Standard ranges apply to adults; slight variations may exist based on laboratory standards.
Homocysteine (Hcy) is a sulfur-containing amino acid derived from methionine metabolism. It is not incorporated into proteins but serves as an intermediate in the methylation cycle, where it can be remethylated to methionine or converted to cysteine. Elevated levels of homocysteine, known as hyperhomocysteinemia, are associated with a wide range of pathological conditions. Researchers have observed that high plasma homocysteine levels are linked to cardiovascular diseases, neurodegenerative disorders, and other age-related conditions. Clinically, elevated homocysteine is a risk marker for atherosclerosis, stroke, and cognitive impairments, including Alzheimer's disease. It is also implicated in developmental issues such as neural tube defects. For athletes and biohackers, maintaining optimal homocysteine levels is crucial as it may influence cardiovascular health and cognitive function, potentially impacting performance and longevity. Researchers found that interventions such as B vitamin supplementation can reduce homocysteine levels, potentially mitigating associated risks. However, factors such as genetic predispositions, dietary habits, and lifestyle choices can affect homocysteine levels. Time-of-day and fasting status may not significantly influence homocysteine measurements, but certain medications and health conditions can interfere with results. Therefore, understanding and managing these factors is essential for accurate assessment and intervention.
Klinische Bedeutung
Elevated homocysteine levels indicate increased risk for cardiovascular diseases, cognitive impairments, and neurodegenerative disorders. Low levels are less commonly discussed but may reflect nutritional deficiencies.
Progressively rising homocysteine levels suggest increasing risk for cardiovascular and neurodegenerative diseases. Retest in 4 weeks if levels exceed 15 μmol/L.
Falling levels indicate effective intervention or improved nutritional status.
Re-test Interval
4 weeks if outside optimal range
Note:
Consult a healthcare provider before starting any supplementation, especially if you have underlying health conditions.
Draw blood at the same time of day for consistency, as levels may fluctuate.
Testing Frequency
Annually for adults at risk of cardiovascular or cognitive diseases.
Correlated with
Current research suggests that the optimal target levels for homocysteine remain debated, particularly regarding the threshold for intervention and the influence of confounders such as vitamin B12 status and genetic factors. Researchers have not yet established definitive reference ranges for homocysteine in various populations, including those with comorbidities. Additionally, clinical questions remain unanswered regarding the long-term effects of lowering homocysteine on cognitive decline and cardiovascular outcomes in diverse patient groups.
1,053
Total Citations
5
Human/RCT
4.6
Avg. Influence
2025
Latest
This review highlighted the link between homocysteine and various diseases, emphasizing that elevated levels of homocysteine are toxic and associated with health issues like cardiovascular diseases and neurological disorders. Researchers concluded that monitoring homocysteine levels could aid in disease prevention and diagnosis.
Researchers reviewed over 100 diseases associated with high levels of homocysteine, particularly cardiovascular and central nervous system diseases. They found that lowering homocysteine levels through B vitamin treatment could potentially prevent conditions like neural tube defects and cognitive impairment. Values of 10 μmol/L or below are likely safe, while levels above 11 μmol/L may require intervention.
This study evaluated various blood biomarkers for post-stroke cognitive impairment, including homocysteine. Researchers found that homocysteine levels were significantly higher in patients with cognitive impairment after stroke compared to those without. The study suggests homocysteine as a potential biomarker for assessing cognitive outcomes in stroke patients.
Researchers studied homocysteine metabolism in diabetes and found that plasma homocysteine levels were lower in both Type 1 and Type 2 diabetes patients compared to controls. They attributed this reduction to increased activity of specific enzymes involved in homocysteine catabolism.
This study reviewed the role of homocysteine (Hcy) as a pathological biomarker for bone disease. Researchers found that elevated Hcy levels could contribute to osteoporosis and bone loss through oxidative stress, highlighting the need for further investigation into its effects on bone health.
Researchers found that pseudoexfoliation syndrome is associated with elevated homocysteine levels and various systemic diseases, particularly affecting the cardiovascular and central nervous systems. The study underscores the clinical significance of monitoring homocysteine in patients with this syndrome. Elevated homocysteine may indicate underlying health issues.
This study focused on developing a tumor-targeted probe for imaging apoptosis, specifically targeting caspase-3 activity. While not directly related to homocysteine, it highlights advancements in biomarker research for cancer diagnostics. The probe demonstrated enhanced imaging capabilities in tumor cells.
Researchers assessed the significance of elevated homocysteine (Hcy) levels in Parkinson's disease (PD) patients with dementia. The study found that Hcy levels were higher in PD patients with dementia compared to those without, indicating a potential link to cognitive decline.
Researchers performed a meta-analysis to investigate the correlation between serum homocysteine levels and cerebral infarction (CI). They found that CI patients had significantly higher serum homocysteine levels compared to healthy controls, indicating a strong association. The study suggests that monitoring homocysteine levels could be important for early diagnosis and treatment assessment of CI.
Researchers characterized clinical subtypes of Parkinson's disease (PD) and found significant differences in serum homocysteine (Hcy) levels among the identified subtypes. The study suggests that Hcy could be a useful biomarker for stratifying PD severity.
Research publications about Homocystein over time
9totalLog lab results, track trends and optimize your biomarkers over time.
This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer